Management of hyperkalemia: An update for the internist

American Journal of Medicine

Volumn 128, Issue 12, 2015, Pages 1281-1287

  Kovesdy, Csaba P ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chronic kidney disease; Glomerular filtration rate; Hyperkalemia; Mortality; Renin angiotensin aldosterone system; Serum potassium

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BICARBONATE; CALCIUM CHLORIDE; CATION EXCHANGE RESIN; DIURETIC AGENT; FLUDROCORTISONE ACETATE; GLUCONATE CALCIUM; INSULIN; PATIROMER; POLYSTYRENESULFONATE SODIUM; POTASSIUM; SODIUM CHLORIDE; SODIUM ZIRCONIUM CYCLOSILICATE; SPIRONOLACTONE;

CLINICAL PRACTICE; COMPARATIVE STUDY; DIALYSIS; DIET SUPPLEMENTATION; DRUG EFFICACY; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HIGH POTASSIUM INTAKE; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; INTERNIST; LONG TERM CARE; PATHOPHYSIOLOGY; POTASSIUM BLOOD LEVEL; POTASSIUM METABOLISM; POTASSIUM RESTRICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT OUTCOME; BLOOD;

HUMANS; HYPERKALEMIA; POTASSIUM; RISK FACTORS;

EID: 84947862944     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2015.05.040     Document Type: Review

References (55)

1. E.G. Lowrie, and N.L. Lew Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities Am J Kidney Dis 15 5 1990 458 482
2. K. Iseki, H. Uehara, K. Nishime, and et al. Impact of the initial levels of laboratory variables on survival in chronic dialysis patients Am J Kidney Dis 28 4 1996 541 548
3. J. Hayes, K. Kalantar-Zadeh, J.L. Lu, S. Turban, J.E. Anderson, and C.P. Kovesdy Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race Nephron Clin Pract 120 1 2012 c8 c16
4. C.P. Kovesdy, D.L. Regidor, R. Mehrotra, and et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients Clin J Am Soc Nephrol 2 5 2007 999 1007
5. C.P. Kovesdy Management of hyperkalaemia in chronic kidney disease Nat Rev Nephrol 10 11 2014 653 662
6. J.L. Fleet, S.Z. Shariff, S. Gandhi, M.A. Weir, A.K. Jain, and A.X. Garg Validity of the International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission BMJ Open 2 6 2012 e002011
7. L.M. Einhorn, M. Zhan, V.D. Hsu, and et al. The frequency of hyperkalemia and its significance in chronic kidney disease Arch Intern Med 169 12 2009 1156 1162
8. P.E. Drawz, D.C. Babineau, and M. Rahman Metabolic complications in elderly adults with chronic kidney disease J Am Geriatr Soc 60 2 2012 310 315
9. P.A. Sarafidis, R. Blacklock, E. Wood, and et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic Clin J Am Soc Nephrol 7 8 2012 1234 1241
10. B.F. Palmer Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system N Engl J Med 351 6 2004 585 592
11. H. Makani, S. Bangalore, K.A. Desouza, A. Shah, and F.H. Messerli Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials BMJ 346 2013 f360
12. P. Susantitaphong, K. Sewaralthahab, E.M. Balk, S. Eiam-ong, N.E. Madias, and B.L. Jaber Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis Am J Hypertens 26 3 2013 424 441
13. D.N. Juurlink, M.M. Mamdani, D.S. Lee, and et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study N Engl J Med 351 6 2004 543 551
14. G.A. Knoll, A. Sahgal, R.C. Nair, J. Graham, W.C. van, and K.D. Burns Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients Am J Med 112 2 2002 110 114
15. S. Korgaonkar, A. Tilea, B.W. Gillespie, and et al. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study Clin J Am Soc Nephrol 5 5 2010 762 769
16. Q. Xu, F. Xu, L. Fan, and et al. Serum potassium levels and its variability in incident peritoneal dialysis patients: associations with mortality PLoS One 9 1 2014 e86750
17. I.S. Edelman, and J. Leibman Anatomy of body water and electrolytes Am J Med 27 1959 256 277
18. G.H. Giebisch, and S.O. Thier Potassium: physiological and clinical importance L. Siegel, Directions in Cardiovascular Medicine 1977 Hoechst-Roussel Pharmaceuticals Somerville, NJ 48
19. F.H. Epstein Signs and symptoms of electrolyte disorders M.H. Maxwell, C.R. Kleeman, Clinical Disorders of Fluid and Electrolyte Metabolism 3rd ed 1980 McGraw-Hill New York 499 516
20. C. Fisch Electrolytes and the heart J.W. Hurst, The Heart 1982 McGraw-Hill New York 1599 1612
21. Y. Miao, D. Dobre, H.J. Heerspink, and et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial Diabetologia 54 1 2011 44 50
22. H.C. Gonick, C.R. Kleeman, M.E. Rubini, and M.H. Maxwell Functional impairment in chronic renal disease. Studies of potassium excretion Am J Med Sci 261 5 1971 281 290
23. J.J. Bourgoignie, M. Kaplan, J. Pincus, G. Gavellas, and A. Rabinovitch Renal handling of potassium in dogs with chronic renal insufficiency Kidney Int 20 4 1981 482 490
24. J. Laine, and C. Holmberg Renal and adrenal mechanisms in cyclosporine-induced hyperkalaemia after renal transplantation Eur J Clin Invest 25 9 1995 670 676
25. R.J. Glassock, D.A. Goldstein, R. Goldstone, and W.A. Hsueh Diabetes mellitus, moderate renal insufficiency and hyperkalemia Am J Nephrol 3 4 1983 233 240
26. P. Arrizabalaga, J. Montoliu, V.A. Martinez, L. Andreu, P.J. Lopez, and L. Revert Increase in serum potassium caused by beta-2 adrenergic blockade in terminal renal failure: absence of mediation by insulin or aldosterone Proc Eur Dial Transplant Assoc 20 1983 572 576
27. T.E. Edes, and E.V. Sunderrajan Heparin-induced hyperkalemia Arch Intern Med 145 6 1985 1070 1072
28. C. Bismuth, M. Gaultier, F. Conso, and M.L. Efthymiou Hyperkalemia in acute digitalis poisoning: prognostic significance and therapeutic implications Clin Toxicol 6 2 1973 153 162
29. F.R. Buhler, F. Burkart, B.E. Lutold, M. Kung, G. Marbet, and M. Pfisterer Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension Am J Cardiol 36 5 1975 653 669
30. M.R. Weir, and M. Rolfe Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors Clin J Am Soc Nephrol 5 3 2010 531 548
31. M.Z. Molnar, K. Kalantar-Zadeh, E.H. Lott, and et al. Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease J Am Coll Cardiol 63 7 2014 650 658
32. G.L. Bakris, M. Siomos, D. Richardson, and et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group Kidney Int 58 5 2000 2084 2092
33. M.R. Garcia-Palmieri Reversal of hyperkalemic cardiotoxicity with hypertonic saline Am Heart J 64 1962 483 488
34. X.M. Lens, J. Montoliu, A. Cases, J.M. Campistol, and L. Revert Treatment of hyperkalaemia in renal failure: salbutamol v. insulin Nephrol Dial Transplant 4 3 1989 228 232
35. A. Alvestrand, J. Wahren, D. Smith, and R.A. DeFronzo Insulin-mediated potassium uptake is normal in uremic and healthy subjects Am J Physiol 246 2 Pt 1 1984 E174 E180
36. K.E. Schwarz, B.D. Cohen, G.D. Lubash, and A.L. Rubin Severe acidosis and hyperpotassemia treated with sodium bicarbonate infusion Circulation 19 2 1959 215 220
37. M. Allon, and N. Shanklin Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol Am J Kidney Dis 28 4 1996 508 514
38. R.A. DeFronzo Hyperkalemia and hyporeninemic hypoaldosteronism Kidney Int 17 1 1980 118 134
39. K.N. Fordjour, T. Walton, and J.J. Doran Management of hyperkalemia in hospitalized patients Am J Med Sci 347 2 2014 93 100
40. L. Scherr, D.A. Ogden, A.W. Mead, N. Spritz, and A.L. Rubin Management of hyperkalemia with a cation-exchange resin N Engl J Med 264 1961 115 119
41. R.B. Flinn, J.P. Merrill, and W.R. Welzant Treatment of the oliguric patient with a new sodium-exchange resin and sorbitol; a preliminary report N Engl J Med 264 1961 111 115
42. G. Chernin, A. Gal-Oz, E. Ben-Assa, and et al. Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy Clin Cardiol 35 1 2012 32 36
43. M. Emmett, R.E. Hootkins, K.D. Fine, C.A. Santa Ana, J.L. Porter, and J.S. Fordtran Effect of three laxatives and a cation exchange resin on fecal sodium and potassium excretion Gastroenterology 108 3 1995 752 760
44. K.S. Kamel, and M. Schreiber Asking the question again: are cation exchange resins effective for the treatment of hyperkalemia? Nephrol Dial Transplant 27 12 2012 4294 4297
45. R.H. Sterns, M. Rojas, P. Bernstein, and S. Chennupati Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 21 5 2010 733 735
46. J.L. Chelcun, R.A. Sable, and K. Friedman Colonic ulceration in a patient with renal disease and hyperkalemia JAAPA 25 10 2012 34, 37-38
47. Z. Harel, S. Harel, P.S. Shah, R. Wald, J. Perl, and C.M. Bell Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review Am J Med 126 3 2013 264.e9 264.e24
48. B.B. Gerstman, R. Kirkman, and R. Platt Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol Am J Kidney Dis 20 2 1992 159 161
49. M.A. Watson, T.P. Baker, A. Nguyen, and et al. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study Am J Kidney Dis 60 3 2012 409 416
50. B. Pitt, S.D. Anker, D.A. Bushinsky, D.W. Kitzman, F. Zannad, and I.Z. Huang Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial Eur Heart J 32 7 2011 820 828
51. J.M. Buysse, I.Z. Huang, and B. Pitt PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016 Future Cardiol 8 1 2012 17 28
52. M. Kosiborod, H.S. Rasmussen, P. Lavin, and et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial JAMA 312 21 2014 2223 2233
53. D.K. Packham, H.S. Rasmussen, P.T. Lavin, and et al. Sodium zirconium cyclosilicate in hyperkalemia N Engl J Med 372 3 2015 222 231
54. M.R. Weir, G.L. Bakris, D.A. Bushinsky, and et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors N Engl J Med 372 3 2015 211 221
55. L.S. Weisberg Management of severe hyperkalemia Crit Care Med 36 12 2008 3246 3251